AzTrials
AzTrials

HivNCT06629753

Differentiated Service Delivery for Pregnant and Postpartum Women Living With HIV and Their Infants

A study testing Differentiated service delivery model in people with Hiv and Transmission Vertical, run by Indiana University at 1 site in Kenya.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Differentiated service delivery (DSD) is an evidence-based HIV care and treatment model endorsed by the World Health Organization (WHO) that simplifies HIV services for clients who are clinically stable, improving the quality and efficiency of HIV services. Read more about this study

Who is it for?
Ages 1 day and olderHealthy volunteers can take part
Conditions the study is for
Hiv, Transmission Vertical, Viremia
What is being tested?
Differentiated service delivery model
Could I receive a placebo?
No, everyone receives an active treatment
How many people
278 participants
Where
1 siteKenya
Study dates
13 Sep 2024to 5 Mar 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 day and older
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Who may be able to join

  • ≥18 years of age
  • Able to understand English or Kiswahili
  • Works as a clinician, nurse, peer counsellor, social worker, pharmacist, or clinic supervisor involved in providing PMTCT services in the maternal-child health clinic at Huruma Sub-District Hospital
  • 5. Woman is ≥15 years of age 6. Woman is enrolled in maternal-child health services at HSDH 7. Woman is living with HIV 8. Woman is able to understand English or Kiswahili

Who cannot join

  • none
  • Eligibility criteria for PPHIV and their infants enrolled prospectively (n=500)
  • Cognitive impairment that would impair participation in the study
  • All infants born to enrolled women during the study will be included.

Trial locations and contacts

1 site in 1 country.

Kenya1 site
  • Huruma Sub-District Hospital

    Eldoret, Uasin Gishu County, 30100

Other trials in Kenya

About this study

Official title: Pilot Implementation of Differentiated Service Delivery for Pregnant and Postpartum Women Living With HIV and Their Infants

Differentiated service delivery (DSD) is an evidence-based HIV care and treatment model endorsed by the World Health Organization (WHO) that simplifies HIV services for clients who are clinically stable, improving the quality and efficiency of HIV services. The goal of this implementation-effectiveness pilot study is to evaluate the implementation of a DSD model for pregnant and postpartum women living with HIV and their infants enrolled in care at Huruma Sub-District Hospital in Kenya.

Read the detailed description

For pregnant and postpartum women living with HIV (PPHIV) in resource-limited settings, maintaining retention in care and viral suppression, and preventing mother-to-child transmission of HIV, are major implementation challenges in the PMTCT cascade. The goal of this study is to execute and evaluate the implementation of a differentiated service delivery (DSD) model for PMTCT to address these challenges. Specifically, this is a pilot study that will evaluate the implementation of a DSD model for PMTCT in a resource-constrained setting in Kenya. The objective of the DSD model is to improve retention in care and viral suppression for PPHIV. In the DSD approach, clinical services are simplified and adapted to the needs and preferences of clients who are clinically stable, allowing the health system to provide intensified services to the clients who unstable according to their needs. Set clinical criteria will be used to determine which PPHIV and their HIV-exposed children are clinically stable and which are unstable. The DSD model will be implemented at Huruma Sub-District Hospital in western Kenya which offers integrated PMTCT services. Over a period of 12 months, all PPHIV that attend this clinic will be recruited to participate in the DSD model as part of the study. The clinical staff will be responsible for triaging PPHIV and their children as stable or unstable according to the DSD eligibility criteria. The implementation success of the DSD model will be determined using the RE-AIM implementation outcomes. This will involve semi-structured interviews with PPHIV and focus group discussions with PMTCT providers participating in the model. Time-motion analysis and medical record review will also be performed to better understand the implementation process and data needed in preparation a future implementation-effectiveness clinical trial. Commensurate with the scope of this pilot implementation study, participants will not be randomized and there will not be a required minimum sample size. The findings from this study will serve as a foundation for a future, large-scale trial to test the effectiveness and implementation of the DSD model for PMTCT in a resource-limited setting.

Being tested
Differentiated service delivery model
Keywords
prevention of mother-to-child transmission, retention, service delivery, maternal-child health, Kenya
Medical subject headings
Acquired Immunodeficiency Syndrome, Viremia, Patient Acceptance of Health Care

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Differentiated service delivery modelBehavioural

    The differentiated service delivery (DSD) intervention is a clinic-level intervention in which PMTCT clients are differentiated into those who are clinically stable or unstable, with each group offered a different package of services to meet their needs. The DSD model that is being tested in this study is an individual-focused, facility-based model designed for implementation within maternal-child health clinics offering integrated HIV services.

Study groups in NCT06629753
Study groupRoleWhat they receive
DSD arm for stable clientsExperimentalPPHIV who meet the following criteria will be considered stable clients: on current antiretroviral therapy ≥6 months; no active illness in the past 6 months; retained in care; viral load <50 copies/mL within the last 6 months; age ≥18 years; not primigravida; not high-risk pregnancy. PPHIV meeting these criteria will be offered postnatal clinic visits monthly for the first 6 months followed by visits every 2-3 months, flexible ART refills, and encounters with a clinician at each visit and mentor mother as needed. Clients who do not meet these criteria will continue to receive standard-of-care services which include monthly visits and ART refills during pregnancy through 18 months postpartum.
Receives: Behavioral: Differentiated service delivery model

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of barriers and facilitators to DSD implementation

    The primary outcome for the analysis in Aim 1 (i.e., the pre-implementation phase) of this study will be the number of barriers/facilitators to implementation as elicited through rapid qualitative analysis of the pre-implementation workshop transcripts

    Measured: One month before implementation of the DSD model in the clinic

  2. Median difference in number of minutes of PMTCT appointment duration before versus after DSD implementation

    The outcome of interest in this analysis will be the difference in clinic encounter durations (i.e., encounters with clinicians, mentor mother) between clients who are classified as stable versus unstable according to the DSD eligibility criteria, as measured through direct observation and time-motion analysis before an after DSD implementation

    Measured: One month before and 6 months after implementation of the DSD model in the clinic

  3. Reach

    The proportion of eligible WLH who sign consent to participate in the study among the total number of WLH who attend the PMTCT clinic during the recruitment periods.

    Measured: One month before and 6 months after implementation of the DSD model in the clinic

  4. Effectiveness, clinic operations level

    The primary outcome will be a ≥20% median reduction in the total clinic visit duration for stable clients compared to their pre-implementation baseline.

    Measured: One month before and during the 12-month period of DSD implementation in the clinic

  5. Proportion of participants who are virally suppressed <50 copies/mL

    Maternal viral suppression will be assessed among all WLH after enrollment in the study during pregnancy and from delivery to 6 months postpartum, 7-12, and 13-18 months postpartum.

    Measured: One month before and during the 12-month period of DSD implementation in the clinic

  6. Proportion of children alive and HIV negative

    HIV-free child survival will be assessed among all children of enrolled WLH from birth to 6, 7-12, and 13-18 months postpartum.

    Measured: One month before and during the 12-month period of DSD implementation in the clinic

  7. Proportion of participants retained in care

    Retention in care will be assessed among all WLH after enrollment in the study during pregnancy and from delivery to 6 months postpartum, 7-12, and 13-18 months postpartum.

    Measured: One month before and during the 12-month period of DSD implementation in the clinic

  8. Proportion of healthcare workers who adopt the DSD model

    The degree to which the clinic commits to and takes on the DSDp model, determined through rapid qualitative analysis of audit/feedback workshop transcripts conducted during the implementation phase

    Measured: During the 12-month period of DSD implementation in the clinic

  9. Proportion of PMTCT clients triaged correctly according to the DSD model

    The proportion of PMTCT clients triaged correctly according to the DSD model eligibility criteria.

    Measured: During the initial 6 months of DSD implementation in the clinic

  10. Proportion of patients who perceive the DSD model to be acceptable

    How satisfactory or agreeable the DSD model is perceived by its end-users, assessed through structured questionnaires administered to patients and providers.

    Measured: During the 12-month period of DSD implementation in the clinic

  11. Proportion of PMTCT clients triaged correctly according to the DSD model at 12 months

    The extent to which a program is part of routine organizational practice, measured through a final time motion analysis and chart review among enrolled participants, conducted over 10 consecutive working days at 6 months at the end of the implementation phase at 12 months

    Measured: At 12 months following the start of DSD implementation in the clinic

  12. Proportion of providers who perceive the DSD model to be acceptable

    How satisfactory or agreeable the DSD model is perceived by its end-users, assessed through structured questionnaires administered to patients and providers.

    Measured: During the 12-month period of DSD implementation in the clinic

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Oct 2024
  2. Study start13 Sep 2024
  3. Primary completion5 Mar 2026
  4. Study completion5 Mar 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Model description
PPHIV and their children identified who are clinically stable will be differentiated to a care pathway that provides simplified PMTCT services that are adapted to their needs and preferences. PPHIV and their children who are clinically unstable will be differentiated to a care pathway that provides intensified PMTCT services.
Masking
None (open label)
Enrolment
278 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06629753
Sponsor's protocol ID
23897
Other IDs
K23HD105495
Status last verified
May 2026
First submitted
2 Oct 2024
Last updated
28 May 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Differentiated service delivery model in people with Hiv and Transmission Vertical, run by Indiana University at 1 site in Kenya.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Kenya. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of barriers and facilitators to DSD implementation (time frame: One month before implementation of the DSD model in the clinic). The study lists 12 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in